James Investment Research Inc Exelixis, Inc. Transaction History

James Investment Research Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 Apr 26, 2019	SELL	$19.6 - $24.76 $1.18 Million - $1.49 Million	-60,225 Closed	0 $0
Q4 2018 Jan 22, 2019	BUY	$13.65 - $21.8 $737,782 - $1.18 Million	54,050 Added 875.3%	60,225 $1.19 Million
Q1 2018 Apr 12, 2018	SELL	$22.15 - $31.89 $1.52 Million - $2.18 Million	-68,480 Reduced 91.73%	6,175 $137,000
Q4 2017 Jan 23, 2018	BUY	$24.23 - $30.93 $318,745 - $406,884	13,155 Added 21.39%	74,655 $2.27 Million
Q3 2017 Oct 13, 2017	BUY	$23.35 - $29.24 $1.44 Million - $1.8 Million	61,500	61,500 $1.49 Million

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of James Investment Research Inc, based on Form 13F filings with the SEC.

Stay updated on James Investment Research Inc with notifications on news.